

## Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy against Brain Tumors

Eduard H. Panosyan<sup>1</sup>, Yuntao Wang<sup>1</sup>, Peng Xia<sup>1</sup>, Wai-Nang Paul Lee<sup>1</sup>, Youngju Pak<sup>1</sup>, Dan R. Laks<sup>2</sup>, Henry J. Lin<sup>1</sup>, Theodore B. Moore<sup>3,4</sup>, Timothy F. Cloughesy<sup>4</sup>, Harley I. Kornblum<sup>2,3,4</sup>, and Joseph L. Lasky III<sup>1</sup>

### Abstract

Targeting amino acid metabolism has therapeutic implications for aggressive brain tumors. Asparagine is an amino acid that is synthesized by normal cells. However, some cancer cells lack asparagine synthetase (ASNS), the key enzyme for asparagine synthesis. Asparaginase (ASNase) contributes to eradication of acute leukemia by decreasing asparagine levels in serum and cerebrospinal fluid. However, leukemic cells may become ASNase-resistant by upregulating ASNS. High expression of ASNS has also been associated with biologic aggressiveness of other cancers, including gliomas. Here, the impact of enzymatic depletion of asparagine on proliferation of brain tumor cells was determined. ASNase was used as monotherapy or in combination with conventional chemotherapeutic agents. Viability assays for ASNase-treated cells demonstrated significant growth reduction in multiple cell lines. This effect was reversed by glutamine in a dose-dependent manner—as expected, because glutamine is the main amino group donor for asparagine synthesis. ASNase treatment also reduced sphere formation by medulloblastoma and primary glioblastoma cells. ASNase-resistant glioblastoma cells exhibited elevated levels of ASNS mRNA. ASNase cotreatment significantly enhanced gemcitabine or etoposide cytotoxicity against glioblastoma cells. Xenograft tumors *in vivo* showed no significant response to ASNase monotherapy and little response to temozolomide alone. However, combinatorial therapy with ASNase and temozolomide resulted in significant growth suppression for an extended duration of time. Taken together, these findings indicate that amino acid depletion warrants further investigation as adjunctive therapy for brain tumors.

**Implications:** Findings have potential impact for providing adjuvant means to enhance brain tumor chemotherapy. *Mol Cancer Res*; 12(5): 694–702. ©2014 AACR.

### Introduction

Targeting cancer metabolism has been safely and effectively used therapeutically since the 1940s, when folate antagonists were used in patients with leukemia (1, 2). For treatment of acute lymphoblastic leukemia (ALL), enzymatic hydrolysis of asparagine (Asn) by asparaginase (ASNase) has received the most attention (3, 4). Asn depletion contributes to clinical eradication of leukemic cells, which are believed to be insufficient in *de novo* Asn biosynthesis. In addition, ASNase

treatment results in deamination of glutamine (5) and decrease of other amino acids (6) in pediatric patients with ALL.

In contrast, there has been less investigation on targeting amino acid metabolism in brain tumors—mostly preclinical studies targeting glutamine use (7), methionine restriction (8), and methionine depletion (9). Brain cells depend on glutamine for normal neurotransmitter function, via  $\gamma$ -aminobutyric acid ligand–receptor interactions (10). Antiglutamine agents as monotherapy have been tested against brain tumors in clinical settings, with limited responses (11, 12). As another approach, antimetabolite regimens exploiting glutamine utilization might improve the sensitivity of some human gliomas and medulloblastomas to chemotherapeutic agents *in vitro* (13, 14). Results suggest that combining antimetabolic approaches with conventional chemotherapy might increase clinical efficacy.

The blood–brain barrier (BBB) is one possible explanation for the relative difficulty in finding efficacious drugs for brain tumors. Thus, ability to bypass the BBB may provide a therapeutic advantage. Large enzymes cannot cross the BBB. However, when ASNase deaminates Asn in the serum, Asn levels decline in the cerebrospinal fluid (CSF; refs. 15–17). Thus, enzymatic depletion of an essential substrate in

**Authors' Affiliations:** <sup>1</sup>Department of Pediatrics, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance; Departments of <sup>2</sup>Psychiatry and Molecular and Medical Pharmacology and <sup>3</sup>Pediatrics; and <sup>4</sup>The Jonsson Comprehensive Cancer Center, University of California Los Angeles (UCLA), Los Angeles, California

**Note:** Supplementary data for this article are available at Molecular Cancer Research Online (<http://mcr.aacrjournals.org/>).

**Corresponding Author:** Eduard H. Panosyan, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, 1000 W. Carson St., Bldg N-25, Box 468, Torrance, CA 90509. Phone: 310-222-4171; Fax: 310-320-2271; E-mail: epanosyan@labiomed.org

doi: 10.1158/1541-7786.MCR-13-0576

©2014 American Association for Cancer Research.

serum—followed by decline in CSF levels—may represent a feasible concept for brain tumor treatment.

Leukemia cells may become ASNase resistant by upregulation of asparagine synthetase (ASNS; ref. 18), which helps restore depleted intracellular Asn levels. There is evidence that certain aggressive solid neoplasms may be associated with ASNS overexpression, such as ovarian (19), prostate (20), and pancreatic cancers (21). In this study, we demonstrate that enzymatic amino acid depletion may synergistically enhance brain tumor cell death caused by traditional DNA-damaging agents. In addition, we look at molecular mechanisms by which synergism may be occurring between ASNase and temozolomide. These studies serve as a proof-of-principle for altering amino acid metabolism as a potential adjunct to brain tumor chemotherapy.

## Materials and Methods

### Cell lines

We primarily used 4 brain tumor cell lines (3 human and 1 mouse): DAOY, a pediatric medulloblastoma line with moderate temozolomide sensitivity (22), inducible alkylator resistance (23), and a well-established nude mouse xenotransplant model (24); GBM-ES and U87, both p53 and PTEN null human glioblastoma lines with reported temozolomide and radiation resistance (25); and GL-261, a mouse glioma cell line for which an *in vivo* model was sensitive to a ketogenic diet (26)—suggesting metabolic vulnerability. DAOY, GL-261, and U87 cell lines were all purchased from American Type Culture Collection and verified according to their procedures. The GBM-ES and 235, a pediatric medulloblastoma (27) cell line, were generated from patient samples collected at University of California Los Angeles (UCLA; via an Institutional Review Board-approved protocol) and authenticated using morphology analysis and growth curve analysis. All cell lines tested negative for mycoplasma.

### Cell proliferation assays for serum cultures

ASNase ± other chemotherapeutic agents were tested against medulloblastoma and glioblastoma cell lines, *in vitro*, by the assays utilizing MTS (5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-2-thiazolyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt) (28). Analysis of cell viability was performed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay system (Promega). Cells were seeded at  $2.5 \times 10^3$  cells per well in 96-well plates and incubated at 37°C in a humidified chamber with 5% CO<sub>2</sub> for 24 hours before treatment. Twenty microliters of CellTiter 96 AQueous One Solution reagent was added to each well 72 hours after treatment with various drug combinations. Absorbance was recorded at 490 nm after 2 hours. Background wells containing neither cells nor drug were used for subtraction and final absorbance calculations. Three wells per condition were used for calculating means and SDs for combinations of agents ± ASNase and for glutamine rescue experiments.

### Analysis of ASNS mRNA expression by real-time RT-PCR

ASNS expression was measured by real-time RT-PCR (RT-PCR) in cell lines before and after treatment with

ASNase ± temozolomide (21, 29). mRNA from a housekeeping gene (18S) was used as an internal standard for the total amount of cDNA. Total RNA was extracted from cultured cells (RNeasy Mini Kit; Qiagen). One microgram of total RNA was used for first strand cDNA synthesis, using a poly-T20 primer (Transcriptor First Strand cDNA Synthesis Kit; Roche). The synthesized cDNA was used as a template for RT-PCR (Fast SYBR Green I Master Mix; Applied Biosystems). Primers for cDNA amplification were ASNS-forward, CTGCACGCCCTCTATGACA; ASNS-reverse, TAAAAGGCAGCCAATCCTTCT; 18S-forward, GGACAGGATTGACAGATTGATAGC; and 18S-reverse, TGGTTATCGGAATTAACCAGACAA.

Thermal cycling consisted of 45 cycles of denaturation for 30 seconds at 90°C; annealing for 30 seconds at 58°C; and extension for 40 seconds at 72°C. Relative amounts of target mRNA were calculated using the comparative cycle threshold (C<sub>t</sub>) method by normalizing levels of target mRNA C<sub>t</sub> to levels of 18S mRNA. Relative enhancements of ASNS mRNA (expressed as a fold increase) were compared after incubating cells under different conditions (e.g., ASNase and/or temozolomide for 24, 48, or 72 hours).

### Neurosphere assays for ASNase sensitivity

DAOY and GBM-ES cells were plated in neurosphere culture media at low density (400 cells per well in 96-well plates), immediately after enzymatic dissociation into single-cell suspensions (27, 30, 31). A separate 96-well plate for each cell line was used for neurosphere formation. Cells were treated with different concentrations of ASNase (0.0625 to 2 IU/mL; 12 wells/concentration; 100 µL/well). Each plate also included wells with untreated cells (controls). Neurosphere cultures were supplemented weekly with an EGF/fibroblast growth factor + heparin mixture in 10 µL of fresh media (30). Plates were monitored closely for formation of neurospheres, which were counted after a density of 10 to 20 neurosphere/well was achieved for untreated controls. This assay evaluated concentration-dependent reduction of presumably clonal neurosphere numbers.

### Amino acid analysis

Serum samples from 3 mice and cell supernatants from 3 cell lines, along with control media, were sent to the Molecular Structure Facility at the University of California, Davis, for amino acid analysis (overnight on dry ice). Sample processing and amino acid levels were as described (<http://msf.ucdavis.edu/amino-acid-analysis/>; ref. 32). Briefly, an L-8900 Hitachi amino acid analyzer was used, and amino acids were quantified using a lithium citrate buffer system. The analyzer uses ion-exchange chromatography to separate amino acids and a "post-column" ninhydrin reaction for detection—sensitive to the pmol level (~100 pmol). Physiologic samples were acidified with sulfosalicylic acid to remove any intact proteins before analysis.

### Mouse experiments

All mouse experiments complied with guidelines of the Institutional Animal Care and Use Committee of the Los

Angeles Biomedical Research Institute. We used severe combined immunodeficient (SCID) mice with heterotopic subcutaneous xenografts with DAOY cells (24; The Jackson Laboratory; all males, 6-week-old at the time of tumor transplantation). Tumor cells ( $1 \times 10^7$ ) were injected under the skin in the right flank. Three weeks after transplantation, animals were treated according to groupings below (5 animals per group):

- Untreated [dimethyl sulfoxide (DMSO) only—10%, 50  $\mu$ L, 5 days/week for 2 weeks]
- ASNase only (2 IU/g Mondays, Wednesdays, Fridays for 2 weeks)
- Temozolomide only (0.05 mg/g, 5 days/week for 2 weeks), and
- ASNase and temozolomide at the same doses and for the same duration as above.

Tumors were measured with digital calipers 3 times a week. Animals were euthanized when tumors reached 1.5 cm in length. An ellipsoid volume formula was used to calculate tumor volumes ( $1/2 \times \text{length} \times \text{width}^2$ ; ref. 33). Mice were weighed 2 to 3 times a week throughout the experiment.

#### Asparaginases and cell culture media

All experiments used *E. coli* asparaginase. For *in vitro* asparaginase sensitivity and combination experiments, we used Dulbecco's Modified Eagle Medium (DMEM) medium with 862 mg/L of GlutaMAX (Gibco; Life Technologies) and 10% FBS. Treatment was with Elspar asparaginase (Lundbeck Inc.). For neurosphere cultures and assays, DMEM/F12 media (with 365 mg/L of L-glutamine and 7.5 mg/L of L-asparagine; Gemini Bio-Products) was used with a one-time addition of L-glutamine. For glutamine rescue (at 1 and 10 mmol/L) and ASNS PCR-related experiments, DMEM without L-asparagine or L-glutamine (Cellgro) was used, supplemented with 10% FBS. ASNase was from Sigma-Aldrich (for animal treatment) or ProSpec (for ASNS PCR experiments). Temozolomide (CGene-Tech) was dissolved in DMSO. The same amounts of DMSO (1%) were also used for control and ASNase treatment groups (without temozolomide).

#### Statistical methods

Graph pad PRISM 6.0 statistical software and Excel programs were used to plot and analyze data. For most *in vitro* effects, absorbance readings of untreated (i.e., vehicle treated) cells were used for control values. Reductions in cell growth are expressed as a percentage of control. For glutamine rescue experiments, absorbance readings are shown as absolute numbers. For neurosphere assays, absolute numbers of neurospheres in untreated wells were used as 100% levels. Numbers representing treated neurospheres are reported as a percentage of control.

The paired two-tailed Student *t* test was used to compare *in vitro* growth with DNA-damaging agents alone versus ASNase combined with these agents.

For statistical analyses of our *in vivo* mouse experiments, we used two-way repeated measures ANOVA to compare tumor volume changes for the two drugs (ASNase and temozolomide). The two drugs were considered between-subject factors, whereas time (i.e., date) was considered a within-subject factor. A two-way interaction between the two drugs, and a three-way interaction between the two drugs and time were included in the model to test for possible synergy between the two drugs (34). Differences in least square means (LS means) were computed and tested among all four pairs at a given time. The Tukey method was used for multiple comparison adjustments for the *P* values and confidence intervals for the differences between LS means. A residual analysis was conducted to check model assumptions. Log transformations were applied to tumor volumes for better model fitting, and to satisfy the normality assumption for ANOVA. The *in vivo* data analyses were done using SAS 9.3. *P* values of <0.05 were used as the cutoff for statistical significance. The Chou–Talalay method was considered to be unfeasible for the analysis, because its main prerequisites are dose–effect curves for each drug alone and for the combination. Large sample sizes would be required to determine ED50 values *in vivo*. However, the nearly complete lack of response to ASNase monotherapy in mice makes generation of such dose–response curves impractical.

Relative expression levels of ASNS mRNA measured by RT-PCR were also compared with values for untreated controls. All data were corrected for differences in total mRNA by use of the 18S mRNA internal control.

## Results


### Asparaginase activity against brain tumor cells *in vitro*

ASNase treatment *in vitro* resulted in dose-dependent and variable growth inhibition of 4 brain tumor cell lines, as measured by MTS assays. DAOY medulloblastoma cells were the most sensitive to ASNase, compared with the human glioblastoma multiforme (GBM) and mouse glioma lines (Fig. 1A).

Neurosphere formation was used to evaluate *in vitro* inhibitory effects of ASNase monotherapy on putative stem-like brain tumor cells. We found reductions in neurosphere numbers for cells treated with different doses of ASNase (Fig. 1B). Again, DAOY medulloblastoma cells had better ASNase sensitivity compared with GBM-ES glioblastoma cells.

### Reversal of ASNase effects by glutamine *in vitro*

Glutamine, the main amino donor for ASNS, can enhance intrinsic Asn synthesis and counteract ASNase effects. To test this hypothesis, we conducted "glutamine rescue" experiments, in which cells were cultured without or with glutamine (at two concentrations). Cells were grown with or without ASNase. Glutamine stimulated cell growth in untreated cells. Moreover, dose-dependent reversal of ASNase-induced cell inhibition was observed in medulloblastoma and GBM cell lines (Fig. 2A and B). Dose



**Figure 1.** A, asparaginase effects on 4 brain tumor cell lines measured by MTS assays. Medulloblastoma cells are the most sensitive, and GBM-ES cells are the most resistant. B, asparaginase effects on neurosphere formation are more pronounced in medulloblastoma cells compared with GBM-ES cells.

dependency of glutamine rescue was more evident in DAOY cells, compared with U87.


#### Asparaginase cotreatment enhances cytotoxicity of DNA-damaging agents *in vitro*

We tested whether cotreatment with asparaginase potentiates cytotoxicity of agents that damage DNA or affect DNA synthesis or repair. GBM-ES cells were used, because they were the most resistant to ASNase, of the 4 lines (Fig. 1A), and thus most likely to reveal additive or synergistic effects. Cotreatment of GBM-ES cells with gemcitabine or etoposide (VP-16) with ASNase (0.25 IU/mL) resulted in significantly more cell reduction (20%–50% as measured by MTS), compared with treatment with gemcitabine or VP-16 alone (Fig. 3A and B). ASNase alone (0.25 IU/mL) caused GBM-ES growth reductions of only approximately 15%. Dose responses for GBM-ES cells were augmented by approximately 20% when ASNase was added to gemcitabine (Fig. 3A). Considering that 0.25 IU/mL of ASNase alone induced 15% cell reduction, the result for the combination is more consistent with an additive effect, with  $P = 0.046$  ( $t$  test). In contrast, addition of ASNase to etoposide enhanced cell reduction up to 50% or more, with  $P = 0.017$  (Fig. 3B), more suggestive of synergistic interaction.

#### Amino acids pre- and post-ASNase treatment


Serum amino acid levels were measured in 3 SCID mice. Two were treated with intraperitoneal ASNase (2 IU/g of body weight), and the other was a control. Retro-orbital blood samples were obtained 24 and 72 hours after ASNase doses. Results showed sustained deamination of Asn 24 and 72 hours after ASNase doses. Specifically, pretreatment serum Asn levels were 37.4 nmol/mL, compared with 0 nmol/mL after 24 and 72 hours. *In vivo* Gln levels were in the 1,000 nmol/mL range and did not decrease 24 or 72 hours post-ASNase in mouse serum samples. However, glutamic acid levels doubled to 125 nmol/mL 24 hours post-ASNase, returning to 68 nmol/mL at 72 hours (comparable with baseline). On the other hand, aspartic acid levels were 30.9 nmol/mL before treatment, compared with 53 nmol/mL after 24 and 72 hours—compatible with more deamination of Asn to aspartic acid than for glutamine to glutamic acid.

Glutamine measurements in cell supernatants from 3 lines consistently demonstrated  $\geq 80\%$  glutamine deamination after 24 hours of treatment with 0.5 IU/mL of ASNase, whereas aspartic and glutamic acids increased 2- and 25-fold, respectively (Supplementary Fig. S1).



**Figure 2.** Glutamine addition rescues cells treated with ASNase. Dose dependency of the glutamine rescue effect is pronounced in more ASNase-sensitive DAOY medulloblastoma cells (A), compared with relatively resistant U87 glioblastoma cells (B).






**Figure 3.** *In vitro* treatment of GBM-ES cells with combinations of gemcitabine  $\pm$  ASNase (A) and etoposide  $\pm$  ASNase (B). Both show significant augmentation of cytotoxic effects against GBM-ES by the addition of ASNase.

#### Possible synergistic effects of ASNase and temozolomide in combination *in vivo* (Fig. 4)

Tumor growth for controls and animals treated with ASNase alone was identical ( $P = 1$ ; Table 1). Temozolomide alone provided modest suppression of tumor growth, although significantly better than for controls or ASNase alone ( $P < 0.05$ ). However, more pronounced growth suppression occurred with the ASNase and temozolomide



**Figure 4.** *In vivo* tumor growth in 4 groups of animals treated with vehicle only, ASNase only, temozolomide only, or combination therapy. Each data point represents measurements of 5 tumors in SCID mice (20 mice total). Each line represents tumor growth kinetics in 5 mice. Addition of ASNase to temozolomide significantly suppressed tumor growth ( $P = 0.035$ ; repeated measure ANOVA, Table 1). Note the tumor growth accelerations after cessation of therapy.

combination, compared with temozolomide alone (Fig. 4; Table 1;  $P = 0.035$ ). Results suggest possible synergy between the 2 agents ( $P = 0.055$  for the interaction). On average, tumors in the combination group were half the size of tumors in the temozolomide-only group. The effect started 10 days after initiation of therapy and lasted roughly 3 weeks, when curves gradually merged. Transient decreases in tumor volume with ASNase + temozolomide treatment strongly suggest cell death with these agents, in addition to slowing of growth. (Cell death is also supported by near-complete eradication of DAOY cells by ASNase observed *in vitro*, Fig. 1.)

#### Weights of mice in relation to ASNase treatment


Animals were weighed at the time of tumor measurements and drug administration (Fig. 5). There were no significant weight differences with ASNase alone, compared with controls. There was 5% to 10% weight loss with temozolomide. However, addition of ASNase did not change weights significantly.

**Table 1.** Repeated measures ANOVA for comparison of tumor volume changes among four groups

Compared animal groups ( $n = 5$ in each group)	Difference in LS means <sup>a</sup>	Confidence interval	Adjusted $P$ value
Control vs. ASNase only	0.027	-0.63-0.69	0.999
Control vs. TMZ only	0.7	0.04-1.36	0.036
Control vs. ASNase and TMZ	1.4	0.74-2.1	0.0001
ASNase only vs. TMZ only	0.67	0.01-1.34	0.046
ASNase only vs. ASNase and TMZ	1.38	0.7-2.04	0.0001
TMZ only vs. ASNase and TMZ	0.7	0.04-1.36	0.035

Abbreviation: TMZ, temozolomide.

<sup>a</sup>LS means on a logarithmic scale.



**Figure 5.** Body weight changes in 4 treatment groups. Weight loss occurred mostly in temozolomide-treated animals. Weight gain resumed after cessation of therapy.

### ASNS mRNA expression in relation to ASNase sensitivity *in vitro*

ASNS expression was measured by RT-PCR in 3 human brain tumor cell lines, at baseline and after 4 different treatments (24, 48, and 72 hours following treatment; Fig. 6). ASNS mRNA expression increased in all 3 cell lines through 24 to 72 hours (Fig. 6). However, less upregulation of ASNS occurred in DAOY medulloblastoma cells (which are the most sensitive to ASNase), compared with U87 and GBM-ES glioblastoma lines (Fig. 6).


Temozolomide seemed to induce similar (or less) ASNS mRNA overexpression in glioblastoma lines, compared with ASNase (Fig. 6). Temozolomide combined with ASNase resulted in ASNS upregulation patterns similar to those seen for temozolomide monotherapy in medulloblastoma, and for ASNase monotherapy in glioblastoma cells.

## Discussion

### Asparagine in various cancers

Targeting cancer metabolism for therapeutic purposes has been one of the cornerstones of successful ALL treatment (1, 3), but the clinical role of the antimetabolite approach for treatment of solid tumors is less established (2). Traditionally, Asn metabolism has been considered a target for certain hematologic malignancies (3). However, recent research shows that upregulated ASNS is also associated with biologic

**Figure 6.** A, DAOY cells; B, U-87 cells; and C, GBM-ES cells. ASNS mRNA measured by RT-PCR in 3 human cell lines at different time points after exposure to different treatments. At 24 hours of ASNase exposure, sensitive medulloblastoma cells have lower overexpression of ASNS mRNA (although ASNS mRNA production is increased over baseline), compared with cells exposed only to the vehicle (DMSO). In contrast, noticeable increases in ASNS (compared with levels in untreated cells) were observed in more resistant glioblastoma cell lines at 24 hours after ASNase  $\pm$  TMZ (temozolomide) exposure. Temozolomide treatment alone induces comparable or less ASNS mRNA expression in glioblastoma lines, compared with treatment with ASNase alone.



aggressiveness of ovarian (19), prostate (20), and pancreatic (21) cancers. Therefore, enzymatic amino acid depletion could conceivably become useful for a variety of malignancies (35).

#### Amino acid metabolism in brain tumors

In an earlier study of free amino acids in the CSF, there were lower levels of Asn, valine, and leucine among patients with glioblastomas and low-grade gliomas, compared with controls (36). Recently, it was shown that certain GBMs express high levels of the enzyme that initiates catabolism of branched-chain amino acids (valine, leucine, and isoleucine), making their metabolism a possible target for GBM treatment (37). Similarly, deprivation of certain other amino acids may sensitize brain tumor cells to chemotherapy, as supported by our *in vitro* and *in vivo* data for Asn.

Interestingly, glutamine reversed growth inhibition by ASNase in our *in vitro* experiments. Glutamine plays a crucial role in the metabolism of neoplastic cells, including glioma cells (14). Cell rescue from ASNase by glutamine is expected, because abundant glutamine may augment *de novo* Asn biosynthesis by serving as a main amino group donor for ASNS (4). Transfection of a human glioblastoma cell line with liver-type glutaminase downregulates the DNA-repair gene, O(6)-methyl guanine methyl transferase, and sensitizes cells to alkylating agents (38). It is possible that effects in our experiments might be partly explained by glutamine deamination, because ASNase also catalyzes the conversion of glutamine into glutamate (4, 5), especially *in vitro* (Supplementary Fig. S1). Unchanged glutamine levels in mice may be partly responsible for lack of *in vivo* response to ASNase monotherapy (Fig. 4).

#### Combining ASNase with cytotoxic agents

ASNase cotreatment increased antitumor activity of various agents that interfere with DNA integrity and repair in our *in vitro* GBM and *in vivo* medulloblastoma models. A hypothesized mechanism is temozolomide-induced DNA damage, which may limit the cell's ability to produce sufficient ASNS to compensate for Asn depletion. However, our results do not directly support decreased ASNS mRNA expression induced by temozolomide (because temozolomide and ASNase were associated with similar ASNS mRNA expression in glioblastoma lines, compared with ASNase alone).

However, glioblastoma cells were capable of more sustained ASNS mRNA upregulation (after 24 hours of ASNase exposure) and were more resistant to both ASNase and cytotoxic monotherapy. In contrast, medulloblastoma cells had less ASNS mRNA overexpression (compared with untreated control cells at 24 hours) and were more sensitive to ASNase. Efficacy of combination treatment against ASNase-resistant GBM-ES cells suggests that cytotoxics may sensitize cells to Asn depletion. The drugs in these combinations were administered simultaneously. However, the

sequence of drug administration may be relevant and should be investigated in future research.

#### Asparaginase and stem-like brain tumor cells

Targeting glycolysis in gliomas is another antimetabolic approach that has been considered, but it may spare glioma stem cells (GSC; ref. 39). Thus, alternative antimetabolic approaches against GSCs are needed, such as targeting amino acid metabolism. Our data confirm ASNase activity against cells transferred to neurosphere conditions, which mimic GSCs. Further *in vitro* and *in vivo* testing is needed to verify that ASNase (alone or combined with chemotherapy) can affect proliferation or survival of the putative stem-like population in brain tumors.

#### ASNase and temozolomide tolerability in mice

Asparaginase is not particularly myelosuppressive—another desirable characteristic of amino acid depletion in combination therapy. Mouse weight data (as a crude measure of toxicity) tentatively support the tolerability of this combination in our model. However, use of ASNase in the treatment of leukemia has been reported to cause bleeding in the CNS, which might be a contraindication to the clinical use of this combination therapy. Further preclinical testing of intracranial models will allow careful monitoring for intracranial hemorrhage. In addition, fibrinogen levels may provide clinical information on this theoretical risk.

#### Amino acid depletion in CSF

ASNase has been clinically administered intramuscularly and intravenously. As mentioned above, ASNase does not cross the BBB. However, both routes are effective for leukemia therapy (16, 17). Therefore, Asn depletion in the CSF depends on depletion of Asn in the blood (16, 17). A disrupted BBB in brain tumors (40) may allow more penetration of enzymatic proteins into the CSF and tumor bed, with better therapeutic effects. The intrathecal route may also be an option for testing in preclinical models of GBM.

Enzymatic depletion of a substrate in the serum, with subsequent decreases in the CSF, seems to be a feasible approach for brain tumor therapy development. One or more amino acids may be therapeutic targets for brain tumors due to high amino acid uptake (41), which is independent of BBB disruption (40). The uptake likely reflects high expression of amino acid transporters in gliomas (41) and serves as a basis for radiolabeled amino acid imaging for diagnosis or assessing treatment responses (42). Whether any particular amino acid has greater importance in brain tumors—like Asn for ALL or perhaps arginine for hepatocellular carcinoma (43)—remains to be seen. Last, small-molecule inhibitors for ASNS that are being investigated for hematologic malignancies (44) and similar antimetabolic approaches (38) may have value in future research.

## Conclusions

Pharmacologic depletion of selected amino acids may serve as an adjunct to enhance cytotoxic therapy against brain tumors. An asparaginase and temozolomide combination was effective and well tolerated in our heterotopic medulloblastoma model. Design of further preclinical studies should include intracranial models and pharmacodynamic analysis of amino acids.

## Disclosure of Potential Conflicts of Interest

H.I. Kornblum received a commercial research grant from Celgene Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.

## Authors' Contributions

**Conception and design:** E.H. Panosyan, W.-N.P. Lee, H.I. Kornblum, J.L. Lasky III  
**Development of methodology:** E.H. Panosyan, Y. Wang, P. Xia, J.L. Lasky III  
**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** E.H. Panosyan, Y. Wang, D.R. Laks, T.B. Moore, T.F. Cloughesy, H.I. Kornblum

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** E.H. Panosyan, P. Xia, Y. Pak, D.R. Laks, H.I. Kornblum, J.L. Lasky III

**Writing, review, and/or revision of the manuscript:** E.H. Panosyan, W.-N.P. Lee, H.J. Lin, T.B. Moore, T.F. Cloughesy, J.L. Lasky III

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** E.H. Panosyan, T.F. Cloughesy, J.L. Lasky III

**Study supervision:** E.H. Panosyan, H.I. Kornblum, J.L. Lasky III

## Acknowledgments

The authors thank the Molecular Structure Facility/Proteomics Core at the University of California, Davis, for amino acid analysis.

## Grant Support

This project was supported by a seed grant from the Los Angeles Biomedical Research Institute (20673-01), a Scholars Award from the NIH/NCATS UCLA CTSA UL1TR000124, and NINDS grant NS052563.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 30, 2013; revised January 22, 2014; accepted January 23, 2014; published OnlineFirst February 6, 2014.

## References

- Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). *N Engl J Med* 1948;238:787-93.
- Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. *Nat Rev Drug Discov* 2011;10:671-84.
- Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from childrens cancer study group. *Cancer Res* 1979;39:3893-6.
- Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. *Clin Pharmacokinet* 2005;44:367-93.
- Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). *Anticancer Res* 2004;24:5.
- Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). *In Vivo* 2004;18:107-12.
- Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. *Int J Cancer* 2010;127:2478-85.
- Najim N, Podmore ID, MCGOWN A, Estlin EJ. Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. *Anticancer Res* 2009;29:3103-8.
- Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, et al. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. *Cancer Res* 2001;61:4017-23.
- Albrecht J, Sidoryk-Węgrzynowicz M, Zielińska M, Aschner M. Roles of glutamine in neurotransmission. *Neuron Glia Biol* 2010;6:263-76.
- Taylor SA, Crowley J, Pollock TW, Eyre HJ, Jaeckle C, Hynes HE, et al. Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. *J Clin Oncol* 1991;9:1476-9.
- Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American brain tumor consortium report. *J Clin Oncol* 1999;17:984.
- Dranoff G, Elion GB, Friedman HS, Bigner DD. Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma. *Cancer Res* 1985;45:4082-6.
- Dranoff G, Elion GB, Friedman HS, Campbell GL, Bigner DD. Influence of glutamine on the growth of human glioma and medulloblastoma in culture. *Cancer Res* 1985;45:4077-81.
- Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. *Clin Cancer Res* 2004;10:5335-41.
- Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Würthwein G, Janka-Schaub G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m<sup>2</sup> PEG asparaginase in children with ALL treated according to protocol COALL-06-97. *Pediatr Blood Cancer* 2006;46:18-25.
- Panetta JC, Gajjar A, Hijiya N, Hak LJ, Cheng C, Liu W, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. *Clin Pharmacol Ther* 2009;86:651-8.
- Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. *Biochem J* 2001;357:321-8.
- Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. *Mol Cancer Ther* 2008;7:3123-8.
- Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, et al. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. *Am J Pathol* 2012;180:895-903.
- Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, et al. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. *Cancer Res* 2007;67:3345-55.
- Von Bueren AO, Bacolod MD, Hagel C, Heinemann K, Fedier A, Kordes U, et al. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. *Br J Cancer* 2012;107:1399-408.
- Friedman HS, Colvin OM, Kaufmann SH, Ludeman SM, Bullock N, Bigner DD, et al. Cyclophosphamide resistance in medulloblastoma. *Cancer Res* 1992;52:5373-8.
- Jacobsen PF, Jenkyn DJ, Papadimitriou JM. Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. *J Neuropathol Exp Neurol* 1985;44:472-85.



25. Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, et al. Differential effects of the proteasome inhibitor NPI-0052 against glioma cells. *Transl Oncol* 2010;3:50–5.
26. Stafford P, Abdelwahab MG, Kim do Y, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. *Nutr Metab (Lond)* 2010;7:74.
27. Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, et al. Clinical outcome in pediatric glioma and embryonal brain tumors correlates with in vitro multipassable neurosphere formation. *Pediatr Blood Cancer* 2010;55:644–51.
28. Levy JM, Thorburn A. Modulation of pediatric brain tumor autophagy and chemosensitivity. *J Neurooncol* 2012;106:281–90.
29. Irino T, Kitoh T, Koami K, Kashima T, Mukai K, Takeuchi E, et al. Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression. *J Mol Diagnostics* 2004;6:217–24.
30. Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. *Mol Cancer Ther* 2011;10:1818–28.
31. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. *Stem Cells* 2009;27:980–7.
32. Cooper C, Packer N, Williams K. Amino acid analysis protocols. *Methods in Molecular Biology*, Totawa, NJ: Humana Press; 2000.
33. Reynolds CP, Sun BC, DeClerck YA, Moats RA. Assessing growth and response to therapy in murine tumor models. *Methods Mol Med* 2005;111:335–50. 2005.
34. Slinker BK. The statistics of synergism. *J Mol Cell Cardiol* 1998;30:723–31.
35. Covini DTS, Bussolati O, Chiarelli LR, Paschetto MV, Digilio R, Valentini G, et al. Expanding targets for a metabolic therapy of cancer: L-asparaginase. *Recent Pat Anticancer Drug Discov* 2012;7:4–13.
36. Piek J, Adelt T, Huse K, Bock WJ. Cerebrospinal fluid and plasma aminograms in patients with primary and secondary tumors of the CNS. *Infusionsther Klin Ernahr* 1987;14:73–7.
37. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. *Nat Med* 2013;19:901–8.
38. Szeliga M, Zgrzywa A, Obara-Michlewska M, Albrecht J. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. *J Neurochem* 2012;123:428–36.
39. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, et al. Metabolic state of glioma stem cells and nontumorigenic cells. *Proc Natl Acad Sci USA* 2011;108:16062–7.
40. Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR. Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. *J Neurosurg* 2013;119:427–33.
41. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. "Facilitated" amino acid transport is upregulated in brain tumors. *J Cereb Blood Flow Metab* 1998;18:500–9.
42. Langen K-J, Tatsch K, Grosu A-L, Jacobs AH, Weckesser M, Sabri O. Diagnostics of cerebral gliomas with radiolabeled amino acids. *Dtsch Arztebl Int* 2008;105:55–61.
43. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. *J Clin Oncol* 2010;28:2220–6.
44. Richards NGJ, Kilberg MS. Asparagine synthetase chemotherapy. *Annu Rev Biochem* 2006;75:629–54.

# Molecular Cancer Research

## Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy against Brain Tumors

Eduard H. Panosyan, Yuntao Wang, Peng Xia, et al.

*Mol Cancer Res* 2014;12:694-702. Published OnlineFirst February 6, 2014.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1541-7786.MCR-13-0576](https://doi.org/10.1158/1541-7786.MCR-13-0576)

**Supplementary Material** Access the most recent supplemental material at:  
<http://mcr.aacrjournals.org/content/suppl/2014/02/05/1541-7786.MCR-13-0576.DC1>

**Cited articles** This article cites 43 articles, 15 of which you can access for free at:  
<http://mcr.aacrjournals.org/content/12/5/694.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://mcr.aacrjournals.org/content/12/5/694>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.